Rafael Holdings Inc (RFL)

NYSE:RFL

RFL

Rafael Holdings

RESEARCH TOOLSreports

Want to see RFL full AI Analyst Report?

Rafael Holdings (RFL) Price & Analysis

202 Followers

RFL Stock Chart & Stats

$1.22

-$0.03(-1.52%)

At close: Jan 08 4:00 PM EST

$1.22

-$0.03(-1.52%)

Day’s Range― - ―

52-Week Range$1.12 - $2.65

Previous CloseN/A

Volume21.81K

Average Volume (3M)81.34K

Market Cap

$110.29M

Enterprise Value$13.23M

Total Cash (Recent Filing)$30.50M

Total Debt (Recent Filing)$610.00K

Price to Earnings (P/E)―

Beta0.49

Next Earnings

Nov 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.68

Shares Outstanding51,224,976

10 Day Avg. Volume101,467

30 Day Avg. Volume81,339

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)0.53

Price to Sales (P/S)54.22

P/FCF Ratio-2.63

Enterprise Value/Market Cap0.12

Enterprise Value/Revenue13.50

Enterprise Value/Gross Profit17.03

Enterprise Value/Ebitda-0.41

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet With Very Low LeverageVery low debt (~0.8% of equity TTM) materially reduces near-term refinancing risk and gives management flexibility to fund clinical milestones, pursue licensing or support real-estate operations without immediate pressure to restructure, aiding multi‑quarter execution.

Pivotal Phase 3 TransportNPC Completion And FDA Pre‑NDA InteractionCompleting the pivotal trial and engaging the FDA is a structural de‑risking event: it establishes a regulatory path, creates a clear commercialization timeline, and can convert the company from development-stage investor returns into a commercial-stage biotech with recurring revenue potential.

Exclusive MIT License Expanding Alzheimer’s IPAn exclusive MIT license broadens defensible IP for a large, genetically defined Alzheimer’s subgroup, improving strategic optionality for partnering, licensing or indication expansion and strengthening long‑term pipeline value beyond the NPC indication.

Bears Say

Negative Operating And Free Cash Flow (cash Burn)Sustained negative operating and free cash flow of roughly $13.6M TTM indicates structural cash burn tied to operations and development. This erodes runway, increases probability of dilutive financings or asset sales, and constrains the company’s ability to self‑fund trials or commercialization.

Large, Persistent Net Losses Eroding EquityLarge and recurring net losses are reducing shareholder equity and producing deeply negative ROE. Over multiple quarters this erodes capital cushions, limits reinvestment capacity, and heightens reliance on external capital, which can dilute shareholders and change strategic options.

Very Small Revenue Base And Volatile Operating ResultsRevenue remains tiny relative to costs and has been volatile; high gross margin is offset by fixed development and G&A costs. The mismatch means recurring revenues are insufficient to cover operations, making financial performance dependent on milestones or one‑off events.

Rafael Holdings News

Rafael Holdings reports completion of last patient visit for TransportNPC study

Rafael Holdings (RFL) announced the last patient has completed the final 96-week study visit in the pivotal Phase...

3d ago

RFL

Rafael Holdings Completes Pivotal Phase 3 TransportNPC Study

Rafael Holdings ( ($RFL) ) just unveiled an announcement. On June 10, 2026, Rafael Holdings announced that the...

3d ago

RFL

Rafael Holdings expands Alzheimer’s portfolio with MIT license

Rafael Holdings ( ($RFL) ) has issued an announcement. On April 22, 2026, Rafael Holdings said its subsidiary...

2M ago

RFL

Rafael Holdings Issues Warrants Amid Cyclo Merger

Rafael Holdings ( ($RFL) ) just unveiled an announcement. Rafael Holdings, Inc. has issued 1,078,796 warrants, exercisable for...

6M ago

RFL

Rafael Holdings Reports 2025 Financial Results and Strategic Progress

Rafael Holdings ( ($RFL) ) has released its Q4 earnings. Here is a breakdown of the information Rafael...

8M ago

RFL

Rafael Holdings Appoints Alan Grayson to Board

Rafael Holdings ( ($RFL) ) has shared an update. On October 23, 2025, Rafael Holdings announced the appointment...

8M ago

RFL

Rafael announces data from Cyclo Therapeutics’ Phase 3 TransportNPC study

Rafael announced that data from Cyclo Therapeutics’ Phase 3 TransportNPC open-label, single-arm sub-study evaluating Trappsol Cyclo for Niemann-Pick...

9M ago

RFL

Rafael Holdings Announces Executive Team Changes

The latest update is out from Rafael Holdings ( ($RFL) ). On August 4, 2025, Rafael Holdings announced...

10M ago

RFL

Rafael Holdings Elects N. Scott Fine as Vice Chairman

Rafael Holdings ( ($RFL) ) has shared an update. On July 14, 2025, Rafael Holdings elected N. Scott...

11M ago

RFL

Rafael Holdings Advances Phase 3 Study for NPC1 Treatment

Rafael Holdings ( ($RFL) ) just unveiled an announcement. On June 18, 2025, Rafael Holdings announced the continuation...

12M ago

RFL

Rafael announces continuation of Phase 3 TransportNPC study following DMC review

Rafael Holdings (RFL) announced that its subsidiary Cyclo Therapeutics’ 96-week pivotal phase 3 TransportNPC study evaluating intravenous Trappsol...

12M ago

RFL

Rafael Holdings Reports Improved Financial Results and Strategic Progress

Rafael Holdings ( ($RFL) ) has released its Q3 earnings. Here is a breakdown of the information Rafael...

1y ago

RFL

Rafael Holdings reports Q3 EPS (19c) vs ($1.36) last year

Reports Q3 revenue $362,000 vs $336,000 last year. “We are pleased to have completed our merger with Cyclo...

1y ago

RFL

Rafael Holdings Completes $25M Rights Offering

Rafael Holdings ( ($RFL) ) has shared an announcement. On June 4, 2025, Rafael Holdings, Inc. announced the...

1y ago

RFL

RFL FAQ

What was Rafael Holdings Inc’s price range in the past 12 months?

Rafael Holdings Inc lowest stock price was $1.12 and its highest was $2.65 in the past 12 months.

What is Rafael Holdings Inc’s market cap?

Rafael Holdings Inc’s market cap is $110.29M.

When is Rafael Holdings Inc’s upcoming earnings report date?

Rafael Holdings Inc’s upcoming earnings report date is Nov 02, 2026 which is in 142 days.

How were Rafael Holdings Inc’s earnings last quarter?

Rafael Holdings Inc released its earnings results on Jun 11, 2026. The company reported -$0.082 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.082.

Is Rafael Holdings Inc overvalued?

According to Wall Street analysts Rafael Holdings Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rafael Holdings Inc pay dividends?

Rafael Holdings Inc pays a Semiannually dividend of $0.02 which represents an annual dividend yield of N/A. See more information on Rafael Holdings Inc dividends here

What is Rafael Holdings Inc’s EPS estimate?

Rafael Holdings Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rafael Holdings Inc have?

Rafael Holdings Inc has 51,224,976 shares outstanding.

What happened to Rafael Holdings Inc’s price movement after its last earnings report?

Rafael Holdings Inc reported an EPS of -$0.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 19.101%.

Which hedge fund is a major shareholder of Rafael Holdings Inc?

Currently, no hedge funds are holding shares in RFL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rafael Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

-39.03%

Trailing 12-Months

Asset Growth

-14.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rafael Holdings Inc

Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.